Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™

What happened

Natera presented 18 abstracts, including three oral presentations, at ASN Kidney Week 2026 supporting its Renasight genetic test for chronic kidney disease. One analysis found the median time from a first abnormal kidney indicator to a documented diagnosis was about 5.3 years.

Confirmed

Global impact / market context

Natera is using real-world evidence to argue that genetic testing can shorten the long path to a kidney disease diagnosis. If doctors and payers accept that case, testing volumes for Renasight could grow, supporting the company's revenue and its position in precision medicine.

Analyst inference

The data point to slow diagnosis and limited specialist care in chronic kidney disease, which means patients often reach treatment late. Natera is positioning Renasight as a way to find the cause earlier, which may strengthen its case with doctors and insurers who decide whether tests get used and paid for.

Analyst inference

What to watch

1. Further analyses showed only one third of patients meeting KDIGO-aligned high-risk criteria had any documented nephrology care, and those who did waited a median of 149 days. Confirmed
2. Watch whether Natera shares additional details on payer coverage or clinical adoption for Renasight, since reimbursement decisions determine whether ordering doctors can offer the test routinely. Proposed
3. Watch whether these findings lead kidney specialists to recommend genetic testing earlier, which could raise Renasight order volumes and matter for Natera's testing revenue. Analyst inference

Evidence

• Original source link unavailable